EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A

International Journal of Cancer

Volumn 126, Issue 12, 2010, Pages 2790-2798

  Nagano, Akihito ^a   Ohno, Takatoshi ^a   Shimizu, Katsuji ^a   Hara, Akira ^a   Yamamoto, Takatoshi ^a   Kawai, Gou ^a   Saitou, Mitsuru ^a   Takigami, Iori ^a   Matsuhashi, Aya ^a   Yamada, Kazunari ^a   Takei, Yoshifumi ^b  

^a GIFU UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atelocollagen; Sarcoma; siRNA; VEGF; Xenograft

Indexed keywords

ATELOCOLLAGEN; MESSENGER RNA; RNA BINDING PROTEIN EWS; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FLI 1; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; COLLAGEN; EWS1 WT1 FUSION PROTEIN, HUMAN; EWS1-WT1 FUSION PROTEIN, HUMAN; ONCOPROTEIN; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CAPILLARY DENSITY; CHIMERA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SYNTHESIS; EWING SARCOMA; FUSION GENE; GENE CONTROL; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SARCOMA CELL; TUMOR XENOGRAFT; UPREGULATION; ALTERNATIVE RNA SPLICING; ANIMAL; BONE TUMOR; DRUG SCREENING; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE FUSION; GENETICS; METABOLISM; OSTEOSARCOMA; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ALTERNATIVE SPLICING; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; BONE NEOPLASMS; COLLAGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE FUSION; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; ONCOGENE PROTEINS, FUSION; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SARCOMA, EWING'S; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951925269     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24781     Document Type: Article

References (45)

1. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol 2003;40: 276-287 (Pubitemid 36397630)
2. Fujimura Y, Ohno T, Siddique H, Lee L, Rao VN, Reddy ES. The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator. Oncogene 1996;12: 159-167 (Pubitemid 26041252)
3. Ohno T, Ouchida M, Lee L, Gatalica Z, Rao VN, Reddy ES. The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 1994; 9:3087-3097 (Pubitemid 24296791)
4. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995;11:1049-1054
5. Rao VN, Ohno T, Prasad DD, Bhattacharya G, Reddy ES. Analysis of the DNA-binding and transcriptional activation functions of human Fli-1 protein. Oncogene 1993;8:2167-2173 (Pubitemid 23226950)
6. Ohno T, Rao VN, Reddy ES. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res 1993;53:5859-5863 (Pubitemid 24006149)
7. Dohjima T, Lee NS, Li H, Ohno T, Rossi JJ. Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol Ther 2003;7:811-816 (Pubitemid 36790258)
8. Dohjima T, Ohno T, Banno Y, Nozawa Y, Wen-yi Y, Shimizu K. Preferential downregulation of phospholipase C-beta in Ewing's sarcoma cells transfected with antisense EWS-Fli-1. Br J Cancer 2000;82: 16-19 (Pubitemid 30008952)
9. Nozawa S, Ohno T, Banno Y, Dohjima T, Wakahara K, Fan DG, Shimizu K. Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells. J Biol Chem 2005;280: 27544-27551 (Pubitemid 41076865)
10. Wakahara K, Ohno T, Kimura M, Masuda T, Nozawa S, Dohjima T, Yamamoto T, Nagano A, Kawai G, Matsuhashi A, Saitoh M, Takigami I, et al. EWS-Fli1 upregulates expression of the Aurora A and Aurora B kinases. Mol Cancer Res 2008;6: 1937-1945
11. Yamamoto T, Ohno T, Wakahara K, Nagano A, Kawai G, Saitou M, Takigami I, Matsuhashi A, Yamada K, Shimizu K. Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma. J Cancer Res Clin Oncol 2009;135:1125-1136
12. Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 2004;10: 1344-1353 (Pubitemid 38365227)
13. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246: 1306-1309 (Pubitemid 20066716)
14. Carpenter AE, Sabatini DM. Systematic genome-wide screens of gene function. Nat Rev Genet 2004;5:11-22. (Pubitemid 38055332)
15. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498 (Pubitemid 32494397)
16. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-811 (Pubitemid 28099681)
17. Karagiannis TC, El-Osta A. siRNAs: mechanism of RNA interference, in vivo and potential clinical applications. Cancer Biol Ther 2004;3:1069-1074
18. Ryther RC, Flynt AS, Phillips JA, 3rd, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther 2005;12:5-11.
19. Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer Sci 2006;97:689-696 (Pubitemid 43983779)
20. Zheng L, Liu J, Batalov S, Zhou D, Orth A, Ding S, Schultz PG. An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci USA 2004;101:135-140
21. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002;296:1000-1004
22. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003;327: 761-766 (Pubitemid 36315917)
23. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002;20: 1006-1010
24. Tomar RS, Matta H, Chaudhary PM. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 2003; 22:5712-5715
25. Matta H, Hozayev B, Tomar R, Chugh P, Chaudhary PM. Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol Ther 2003;2:206-210
26. Toub N, Bertrand JR, Tamaddon A, Elhamess H, Hillaireau H, Maksimenko A, Maccario J, Malvy C, Fattal E, Couvreur P. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res 2006;23:892-900.
27. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004;64: 3365-3370
28. Takei Y, Kadomatsu K, Goto T, Muramatsu T. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 2006;107:864-873
29. Ishimoto T, Takei Y, Yuzawa Y, Hanai K, Nagahara S, Tarumi Y, Matsuo S, Kadomatsu K. Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity. Mol Ther 2008;16:387-395
30. Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, Kouno M, Honma K, Nagahara S, Hanai K, Sano A, Kato T, Terada M, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004;32:e109.
31. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y, Hanai K, Kato T, Sano A, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005;102:12177-12182
32. Ochiya T, Nagahara S, Sano A, Itoh H, Terada M. Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines. Curr Gene Ther 2001; 1:31-52.
33. Martinez-Ramirez A, Rodriguez-Perales S, Melendez B, Martinez-Delgado B, Urioste M, Cigudosa JC, Benitez J. Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet 2003;141:138-142
34. Krussel JS, Behr B, Milki AA, Hirchenhain J, Wen Y, Bielfeld P, Lake Polan M. Vascular endothelial growth factor (VEGF) mRNA splice variants are differentially expressed in human blastocysts. Mol Hum Reprod 2001;7:57-63.
35. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart JM, Noel A, Munaut C. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186-3193 (Pubitemid 36759791)
36. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K, Ochiya T. RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 2008;14:939-948
37. Ochiya T, Takahama Y, Nagahara S, Sumita Y, Hisada A, Itoh H, Nagai Y, Terada M. New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med 1999;5:707-710 (Pubitemid 29289437)
38. Burfeind P, Chernicky CL, Rininsland F, Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 1996;93: 7263-7268 (Pubitemid 26243537)
39. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
40. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-936
41. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65:8984-8992
42. Gonzalez I, Vicent S, de Alava E, Lecanda F. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. J Mol Med 2007;85:1015-1029
43. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457-462 (Pubitemid 41724921)
44. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11:263-270
45. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. JClin Oncol 2005;23:939-952